ponatinib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702614
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Ponatinib is a first generation tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases, including FLT3 (reviewed Pemmeraju et al, 2014; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by ponatinib.

Literature References
PubMed ID Title Journal Year
31066629 FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications

Kazi, JU, Rönnstrand, L

Physiol. Rev. 2019
24749672 Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

Cortes, J, Kantarjian, H, Pemmaraju, N, Ravandi, F, Andreeff, M

Expert Opin Investig Drugs 2014
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
GlyCosmos
Authored
Reviewed
Created
Cite Us!